Glycolysis in human cancers: Emphasis circRNA/glycolysis axis and nanoparticles in glycolysis regulation in cancer therapy

Environ Res. 2023 Oct 1:234:116007. doi: 10.1016/j.envres.2023.116007. Epub 2023 Apr 27.

Abstract

The metabolism of cancer has been an interesting hallmark and metabolic reprogramming, especially the change from oxidative phosphorylation in mitochondria to glucose metabolism known as glycolysis occurs in cancer. The molecular profile of glycolysis, related molecular pathways and enzymes involved in this mechanism such as hexokinase have been fully understood. The glycolysis inhibition can significantly decrease tumorigenesis. On the other hand, circRNAs are new emerging non-coding RNA (ncRNA) molecules with potential biological functions and aberrant expression in cancer cells which have received high attention in recent years. CircRNAs have a unique covalently closed loop structure which makes them highly stable and reliable biomarkers in cancer. CircRNAs are regulators of molecular mechanisms including glycolysis. The enzymes involved in the glycolysis mechanism such as hexokinase are regulated by circRNAs to modulate tumor progression. Induction of glycolysis by circRNAs can significantly increase proliferation rate of cancer cells given access to energy and enhance metastasis. CircRNAs regulating glycolysis can influence drug resistance in cancers because of theirimpact on malignancy of tumor cells upon glycolysis induction. TRIM44, CDCA3, SKA2 and ROCK1 are among the downstream targets of circRNAs in regulating glycolysis in cancer. Additionally, microRNAs are key regulators of glycolysis mechanism in cancer cells and can affect related molecular pathways and enzymes. CircRNAs sponge miRNAs to regulate glycolysis as a main upstream mediator. Moreover, nanoparticles have been emerged as new tools in tumorigenesis suppression and in addition to drug and gene delivery, then mediate cancer immunotherapy and can be used for vaccine development. The nanoparticles can delivery circRNAs in cancer therapy and they are promising candidates in regulation of glycolysis, its suppression and inhibition of related pathways such as HIF-1α. The stimuli-responsive nanoparticles and ligand-functionalized ones have been developed for selective targeting of glycolysis and cancer cells, and mediating carcinogenesis inhibition.

Keywords: Cancer metabolism; Chemoresistance; Circular RNAs; Gene delivery; Glycolysis; Nanoparticles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinogenesis
  • Cell Cycle Proteins / metabolism
  • Cell Transformation, Neoplastic
  • Glycolysis
  • Hexokinase / genetics
  • Hexokinase / metabolism
  • Humans
  • Intracellular Signaling Peptides and Proteins / metabolism
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • RNA, Circular / metabolism
  • Tripartite Motif Proteins / metabolism
  • rho-Associated Kinases / metabolism

Substances

  • RNA, Circular
  • Hexokinase
  • MicroRNAs
  • CDCA3 protein, human
  • Cell Cycle Proteins
  • ROCK1 protein, human
  • rho-Associated Kinases
  • TRIM44 protein, human
  • Tripartite Motif Proteins
  • Intracellular Signaling Peptides and Proteins